Research programme: opioid receptor modulators - Alkermes
Alternative Names: ALKS 36; RDC-5768Latest Information Update: 16 Jul 2016
At a glance
- Originator Rensselaer Polytechnic Institute
- Developer Alkermes plc
- Class Small molecules
- Mechanism of Action Opioid delta receptor antagonists; Opioid kappa receptor agonists; Opioid mu receptor antagonists; Opioid receptor agonists; Opioid receptor antagonists; Opioid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Constipation; Pain; Substance-related disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Constipation in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA (PO)